Get started
Markets US Stocks Health Technology Pharmaceuticals: Major

Northwest Biotherapeutics, Inc NWBO

NWBO OTC
NWBO
Northwest Biotherapeutics, Inc OTC
See more on advanced chartSee more on advanced chart
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
See more on advanced chartSee more on advanced chart
Overview
News Ideas Financials Technicals

NWBO Chart

Ideas

NWBO - If you didn’t buy before, now is a good time
NWBO
, 1DLong
NWBO: NWBO - If you didn’t buy before, now is a good time
00:00

Doing a quick breakdown of what I’m seeing on NWBO. A good friend of mine, PennyQueen, has a knack for finding the diamond in the ruff when it comes to OTC stocks. This is one of them. She’s done some great DD on it, and the price appears to be finding it’s footing for another run. However, this is a longer hold...so expect to treat this as an investment and not a...

pop imminent $NWBO
NWBO
, 30Long
NWBO: pop imminent $NWBO

please see previous post about this Stock. Bullish sentiment remains..

$NWBO big bull
NWBO
, 1D
NWBO: $NWBO big bull

so there is not much here to do for TA. The price action has been trading sideways since datalock was announced. i like that the general trend is positive. Feels like MMs (or a few big ass fish) are working to keep price action down + profit taking from those who bought in at the lows of $0.14 . Saying MM and Whales bc level 2 data show a bid/ask spread that...

$NWBO: SmlCap play - Potential 40%+ upside from today's close
NWBO
, 1DLong
NWBO: $NWBO: SmlCap play - Potential 40%+ upside from today's close

see easy and self explanatory boxes on chart for Entry, Exit and Stop loss zones. Never chase. Not for any recommendation, Just an Idea. Like it >> Click 👍/comment, and follow.

NWBO BUY Signal - Risky Penny Stock could Double in Price
NWBO
, 1DLong
NWBO: NWBO BUY Signal - Risky Penny Stock could Double in Price

NWBO BUY Signal - Risky Penny Stock could Double in Price @patels

Technicals

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —
More financials

Profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.

Breaking news

More news